Skip to main content

Table 2 Clinical performance of current screening methods and models for cross-sectional population (CIN2+)

From: Development of models for cervical cancer screening: construction in a cross-sectional population and validation in two screening cohorts in China

   Sensitivity
% (95% CI)
Specificity
% (95% CI)
AUC
(95% CI)
Referral rate
% (95% CI)
Cross-sectional population (N = 1915)     
Current methods in testing set hrHPV DNA (cobas) 92.49 (90.62–94.37) 75.75 (73.26–78.23) 0.84 (0.83–0.86) 50.86 (48.60–53.13)
hrHPV mRNA (Aptima) 93.68 (91.94–95.43) 81.29 (79.11–83.57) 0.87 (0.86–0.89) 48.25 (45.98–50.53)
hrHPV DNA (Onclarity) 91.36 (89.37–93.34) 78.24 (75.78–80.79) 0.85 (0.83–0.86) 49.63 (47.27–51.99)
HPV16/18 DNA (cobas) 75.44 (72.35–78.52) 93.40 (91.86–94.77) 0.84 (0.83–0.86) 33.42 (31.31–35.59)
HPV16/18 E6 66.52 (62.84–69.93) 97.70 (96.70–98.60) 0.82 (0.80–0.84) 28.84 (26.70–31.05)
p16/Ki-67 85.07 (82.33–87.67) 79.41 (76.89–81.67) 0.82 (0.80–0.84) 45.67 (43.40–47.95)
ASC-US+ 95.99 (94.52–97.33) 74.38 (71.72–76.78) 0.85 (0.84–0.87) 53.16 (50.89–55.41)
Co-testing 98.40 (97.33–99.20) 62.04 (59.13–64.70) 0.80 (0.79–0.82) 61.62 (59.40–63.80)
Cross-sectional population validation set (N = 575)     
Logistic regression Base model 92.00 (88.00–95.11) 89.08 (85.63–92.24) 0.91 (0.88–0.93) 42.76 (38.67–46.92)
Base model + E6 92.49 (88.73–95.77) 93.17 (90.44–95.90) 0.93 (0.91–0.95) 42.89 (38.53–47.33)
Base model + GT 92.79 (89.42–96.15) 92.16 (89.22–95.10) 0.92 (0.90–0.95) 42.22 (37.91–46.62)
Base model + E6 + GT 90.31 (86.22–94.39) 94.92 (92.19–97.27) 0.93 (0.90–0.95) 42.04 (37.44–46.74)
Support vector machine Base model 87.11 (82.22–91.56) 92.24 (89.37–94.83) 0.90 (0.87–0.92) 38.92 (34.90–43.05)
Base model + E6 92.96 (89.20–96.24) 88.40 (84.98–91.81) 0.91 (0.88–0.93) 45.85 (41.44–50.30)
Base model + GT 87.02 (82.21–91.35) 91.18 (87.91–94.12) 0.89 (0.86–0.92) 40.47 (36.19–44.85)
Base model + E6 + GT 88.78 (84.18–92.86) 91.80 (88.28–94.92) 0.90 (0.88–0.93) 43.14 (38.52–47.85)
  1. AUC area under the curve, E6 E6 oncoprotein, GT HPV genotyping